Foresite Capital, a multi-stage healthcare and life sciences investment firm with over $3.5 billion under management, announced that it has closed its sixth fund with $900 million in capital commitments. And with this new fund, Foresite Capital continues to invest in technologies ranging from novel therapeutics to companies at the intersection of technology and biotechnology.
Fund VI invests in innovative and growth-oriented companies in three main areas: precision therapeutics, life science infrastructure, and healthcare delivery. These include Alumis, CG Oncology, Latigo, RayThera, and Xaira Therapeutics.
The limited partners of Fund VI include a broad range of investors, among them university endowments, charitable foundations, medical institutions, pension funds, insurance companies, private banks, and family offices worldwide.
Since being established in 2011, Foresite adhered to a data and science-driven investment strategy, resulting in over 47 IPOs, 28 mergers and acquisitions and the approval of 58 drugs by the FDA. And Foresite’s team offers comprehensive support to its portfolio companies, leveraging expertise in company formation, therapeutics product development, and data science / machine learning to provide strategic guidance and technical assistance.
KEY QUOTES:
“Fund VI is deploying capital into what I believe is one of the best biotech investment environments of my career. Advances in biology, genomics and artificial intelligence continue to converge. Biotech innovation is predicting, preventing and treating disease more effectively than ever before. We believe these advances will lead to increasingly efficient investing at all stages.”
- Jim Tananbaum, founder and CEO of Foresite Capital
“We’re grateful for the support we’ve received from both long-standing partners and new investors alike. Their partnership with Foresite Capital enables our support of entrepreneurs who are addressing some of the most vexing aspects of our healthcare system and improving the lives of patients.”
- Hadi Tabbaa, Managing Director and Head of Investor Relations and Business Development
